137 related articles for article (PubMed ID: 29667134)
1. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
Sankhala K; Takimoto CH; Mita AC; Xiong H; Rodón J; Mehrvarz Sarshekeh A; Burns K; Iizuka K; Kopetz S
Invest New Drugs; 2019 Feb; 37(1):76-86. PubMed ID: 29667134
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.
Mehrvarz Sarshekeh A; Xiong HQ; Iizuka K; Hochster HS; Kopetz S
Invest New Drugs; 2018 Oct; 36(5):895-902. PubMed ID: 29948357
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
10. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
Newman EM; Morgan RJ; Kummar S; Beumer JH; Blanchard MS; Ruel C; El-Khoueiry AB; Carroll MI; Hou JM; Li C; Lenz HJ; Eiseman JL; Doroshow JH
Cancer Chemother Pharmacol; 2015 Mar; 75(3):537-46. PubMed ID: 25567350
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
[TBL] [Abstract][Full Text] [Related]
15. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Stevenson JP; DeMaria D; Sludden J; Kaye SB; Paz-Ares L; Grochow LB; McDonald A; Selinger K; Wissel P; O'Dwyer PJ; Twelves C
Ann Oncol; 1999 Mar; 10(3):339-44. PubMed ID: 10355580
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
[TBL] [Abstract][Full Text] [Related]
19. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.
Dent SF; Gelmon KA; Chi KN; Jonker DJ; Wainman N; Capier CA; Chen EX; Lyons JF; Seymour L
Invest New Drugs; 2013 Dec; 31(6):1522-9. PubMed ID: 24072436
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]